FTO and central nervous system cancer: Interestingly, the expression of FTO was significantly deceased in gliomas with malignant clinicopathological features, such as higher WHO grade, mesenchymal subtype, IDH-wildtype status, 1p/19q noncodel and older ages at diagnosis.